263 related articles for article (PubMed ID: 25805312)
1. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy.
Henry AM; Rodda SL; Mason M; Musunuru H; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):382-6. PubMed ID: 25805312
[TBL] [Abstract][Full Text] [Related]
2. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
4. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
[TBL] [Abstract][Full Text] [Related]
5. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
[TBL] [Abstract][Full Text] [Related]
6. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
[TBL] [Abstract][Full Text] [Related]
7. Poor predictive value of intraoperative real-time dosimetry for prostate seed brachytherapy.
Igidbashian L; Donath D; Carrier JF; Lassalle S; Hervieux Y; David S; Bahary JP; Taussky D
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):605-9. PubMed ID: 18793964
[TBL] [Abstract][Full Text] [Related]
8. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; McKenzie M; Spadinger I; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Lapointe V; Berthelet E; Pai H; Harrison R; Kwa W; Bucci J; Racz V; Woods R
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1432-8. PubMed ID: 19036530
[TBL] [Abstract][Full Text] [Related]
10. Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.
Roshan D; Joyce K; Woulfe P; Gorakati PR; Stock R; Sullivan FJ
Brachytherapy; 2021; 20(4):873-882. PubMed ID: 33840634
[TBL] [Abstract][Full Text] [Related]
11. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
13. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.
Shaikh T; Zaorsky NG; Ruth K; Chen DY; Greenberg RE; Li J; Crawford K; Horwitz EM
Brachytherapy; 2015; 14(3):316-21. PubMed ID: 25454576
[TBL] [Abstract][Full Text] [Related]
14. [Review on the effectiveness of prostate cancer brachytherapy].
Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
[TBL] [Abstract][Full Text] [Related]
15. Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive (125)I monotherapy patients.
Morris WJ; Spadinger I; Keyes M; Hamm J; McKenzie M; Pickles T
Brachytherapy; 2014; 13(1):32-41. PubMed ID: 24126102
[TBL] [Abstract][Full Text] [Related]
16. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
Crook J; Patil N; Ma C; McLean M; Borg J
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
[TBL] [Abstract][Full Text] [Related]
19. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
20. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds.
McLaughlin P; Narayana V; Pan C; Berri S; Troyer S; Herman J; Evans V; Roberson P
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):144-50. PubMed ID: 16243441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
